# A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

> **NCT05730036** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 410 (estimated)

## Conditions studied

- Relapsed Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** Linvoseltamab
- **DRUG:** Elotuzumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05730036
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-18
- **Primary completion:** 2033-04-19
- **Final completion:** 2033-04-19
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730036, "A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05730036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*